How were INSYS Therapeutics' earnings last quarter?

INSYS Therapeutics, Inc. (NASDAQ:INSY) posted its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.33. The specialty pharmaceutical company earned $7.63 million during the quarter, compared to the consensus estimate of $14.95 million. INSYS Therapeutics had a negative trailing twelve-month return on equity of 1,430.37% and a negative net margin of 346.61%. The firm's revenue for the quarter was down 68.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.19) earnings per share.

When did INSYS Therapeutics' stock split?

INSYS Therapeutics's stock split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were issued to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

What other stocks do shareholders of INSYS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INSYS Therapeutics investors own include Cara Therapeutics (CARA) , GW Pharmaceuticals (GWPH) , Zynerba Pharmaceuticals (ZYNE) , Puma Biotechnology (PBYI) , Incyte (INCY) , BioMarin Pharmaceutical (BMRN) , Micron Technology (MU) , (MDVN) (MDVN) and NVIDIA (NVDA) .

NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free INSY Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.23
▼
$65,799,000.00
52-Week Range: N/A

Volume: N/A
Average Volume: 9.52 million shs
Market Capitalization: $21.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get INSYS Therapeutics alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About INSYS Therapeutics Stock (NASDAQ:INSY)

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

INSY Stock News Headlines

March 29, 2024 | forbes.com

How Sam Bankman-Fried’s 25 Year Sentence Stacks Up Against Other Billionaire, Ex-Billionaire Convicts

March 15, 2024 | msn.com

Port Clinton man sentenced for illegal dispensing narcotics

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 12, 2024 | finance.yahoo.com

Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor

March 3, 2024 | msn.com

Meet John Kapoor: The CEO and Founder of Insys Who Played a Role in the Fentanyl Crisis

March 1, 2024 | yahoo.com

Lehighton doctor settles with U.S. for alleged False-Claim Act violations

December 18, 2023 | forbes.com

How Trevor Milton’s 4 Year Prison Sentence Stacks Up Against Other Billionaire And Ex-Billionaire Convicts.

December 5, 2023 | msn.com

Tampa doctor must pay $1.5 million for part in ‘Pain Hustlers’ scheme

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

November 2, 2023 | msn.com

Netflix Pain Hustlers: Ex-Boca school counselor used exotic dancer, models to push fentanyl

November 2, 2023 | msn.com

The Real Inspiration Behind Pain Hustlers' Liza Drake Explained

November 1, 2023 | msn.com

Pain Hustlers on Netflix: Meet the master Boca Raton salesman behind the real Insys story

October 31, 2023 | msn.com

Ex-Boca school counselor used exotic dancer, models to push fentanyl

October 31, 2023 | msn.com

Netflix Pain Hustlers: Former exotic dancer from West Palm Beach sentenced in fentanyl scam

October 31, 2023 | msn.com

‘Pain Hustlers’: The True Story Behind Chris Evans and Emily Blunt’s New Netflix Movie

October 30, 2023 | msn.com

Is Liza Drake From Pain Hustlers A Real Person? Director Explains Emily Blunt's Character

October 30, 2023 | msn.com

A Fictitious Drug Takes Center Stage in 'Pain Hustlers' but Is the Story Itself Also Fake?

October 30, 2023 | msn.com

Florida doctor accepted $160K in bribes to prescribe unnecessary fentanyl, feds say

October 30, 2023 | finance.yahoo.com

Rapport Therapeutics Appoints Chief Financial Officer

October 30, 2023 | msn.com

The Ending of ‘Pain Hustlers,’ Explained

October 30, 2023 | news.yahoo.com

Spray form of fentanyl is one of most dangerous prescribed drugs

October 30, 2023 | msn.com

What Happened To The Real Dr. Jack Neel After Pain Hustlers

October 30, 2023 | msn.com

The True Story That Inspired 'Pain Hustlers,' Explained

October 28, 2023 | msn.com

Pain Hustlers Ending Explained: Why did Liza, Pete, and Jack end up in prison?

October 28, 2023 | msn.com

Chris Evans’ Cringey ‘Pain Hustlers’ Rap Is Inspired By a Real Rap Video Made By Ex-Pharma Executives

October 27, 2023 | msn.com

Is 'Pain Hustlers' Based On A True Story? All About Insys Therapeutics And John Kapoor

October 27, 2023 | msn.com

Is Lonafen A Real Drug In Netflix's Pain Hustlers?

See More Headlines

Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/10/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:INSY
Previous Symbol: NASDAQ:NEOL
CUSIP: N/A
CIK: 1516479
Web: www.insysrx.com
Phone: 480-500-3127
Fax: N/A
Employees: 226
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-124,510,000.00
Net Margins: -346.61%
Pretax Margin: N/A
Return on Equity: -1,430.37%
Return on Assets: -64.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.54
Quick Ratio: 0.50

Sales & Book Value

Annual Sales: $82.08 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.58) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 74,570,000
Free Float: N/A
Market Cap: $21.71 million
Optionable: Optionable
Beta: 3.21

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Steven J. Meyer (Age 62)
Exec. Chairman
Mr. Saeed Motahari (Age 53)
CEO, Pres & Director
Mr. Andrew G. Long
Chief Financial Officer
Dr. Danny L. Tuck
Sr. VP of Quality Operations
Mr. Franc Del Fosse (Age 47)
Sr. VP of Corp. Affairs

Key Competitors

View All Competitors

INSY Stock Analysis - Frequently Asked Questions

How were INSYS Therapeutics' earnings last quarter?: INSYS Therapeutics, Inc. (NASDAQ:INSY) posted its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.33. The specialty pharmaceutical company earned $7.63 million during the quarter, compared to the consensus estimate of $14.95 million. INSYS Therapeutics had a negative trailing twelve-month return on equity of 1,430.37% and a negative net margin of 346.61%. The firm's revenue for the quarter was down 68.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.19) earnings per share.
When did INSYS Therapeutics' stock split?: INSYS Therapeutics's stock split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were issued to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.
What other stocks do shareholders of INSYS Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), (MDVN) (MDVN) and NVIDIA (NVDA).

This page (NASDAQ:INSY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

INSYS Therapeutics (INSY) Stock Price, News & Analysis

About INSYS Therapeutics Stock (NASDAQ:INSY)

INSY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

INSY Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info